Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 2/20 | 0.43 |
| ▸ | CTRC | Q99895 | 1/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.42 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TLR4 | O00206 | 2/20 | 0.41 |
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.41 |
| ▸ | PTGES | O14684 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | MGAM | O43451 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SI | P14410 | 1/20 | 0.40 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.40 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.40 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12154504 | 0.99 | ADRB2 (0.42) | ADRB3CTRCADRB2DNM1LMNA | |
| SCHEMBL1732953 | 0.95 | PPARG (0.44) | ADRB3ADRB2DNM1LMNACYP3A4 | |
| SCHEMBL1733321 | 0.91 | PPARG (0.47) | ADRB3ADRB2DNM1LMNACYP3A4 | |
| SCHEMBL1732896 | 0.86 | ADRB2 (0.46) | ADRB3ADRB2DNM1LMNACYP3A4 | |
| SCHEMBL30639267 | 0.81 | CTRC (0.54) | CTRCLMNACYP3A4MAPTPTGES | |
| SCHEMBL8065096 | 0.81 | KDM4E (0.49) | CTRCPTGESALOX5PPARGPTPN1 | |
| SCHEMBL1733165 | 0.78 | KMT2A (0.54) | ADRB3ADRB2DNM1LMNACYP3A4 | |
| SCHEMBL568454 | 0.76 | CTRC (0.50) | CTRCMAPTPTGESALOX5PPARG | |
| SCHEMBL11521450 | 0.76 | KMT2A (0.53) | CTRCLMNACYP3A4MAPTPTGES | |
| SCHEMBL14565994 | 0.76 | CTRC (0.50) | CTRCLMNACYP3A4MAPTPTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329913-B2 | Carbazole derivative, solvate thereof, or pharmaceutically acceptable salt thereof | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2012-12-11 | — | — | US | disclosed |
| US-8329913-B2 | Carbazole derivative, solvate thereof, or pharmaceutically acceptable salt thereof | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2012-12-11 | — | — | US | disclosed |
| US-8329913-B2 | Carbazole derivative, solvate thereof, or pharmaceutically acceptable salt thereof | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2012-12-11 | — | — | US | disclosed |
| EP-1852433-B1 | CARBAZOLE DERIVATIVE, SOLVATE THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ZERIA PHARM CO LTD (JP) | 2011-11-23 | — | — | EP | disclosed |
| EP-1852433-B1 | CARBAZOLE DERIVATIVE, SOLVATE THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ZERIA PHARM CO LTD (JP) | 2011-11-23 | — | — | EP | disclosed |
| US-20100286210-A1 | Carbazole derivative, solvate thereof, or pharmaceutically acceptable salt thereof | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2010-11-11 | — | — | US | disclosed |
| US-20100286210-A1 | Carbazole derivative, solvate thereof, or pharmaceutically acceptable salt thereof | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2010-11-11 | — | — | US | disclosed |
| US-20100286210-A1 | Carbazole derivative, solvate thereof, or pharmaceutically acceptable salt thereof | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2010-11-11 | — | — | US | disclosed |
| EP-1852433-A1 | CARBAZOLE DERIVATIVE, SOLVATE THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Zeria Pharmaceutical Co., Ltd. (JP) | 2007-11-07 | — | — | EP | disclosed |
| EP-1852433-A1 | CARBAZOLE DERIVATIVE, SOLVATE THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Zeria Pharmaceutical Co., Ltd. (JP) | 2007-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286210-A1 | Carbazole derivative, solvate thereof, or pharmaceutically acceptable salt thereof | CEL, LIPC, CES1 | ADRB3 33/4885CTRC 1087/4885ADRB2 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.